Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Chronic Lymphocytic Leukaemia: Update Bulletin [October 2014]

Product Code:
Release Date:
October 2014

Gain new KOL insights on the latest events happening in Chronic Lymphocytic Leukaemia: Gilead’s Zydelig (idelalisib); Pharmacyclics/Janssen’s Imbruvica (ibrutinib); Imbruvica and Zydelig.

Highlights from this event update bulletin

  • What factors will determine the success of Imbruvica for the treatment of CLL in the EU?
  • Which CLL patients do KOLs favour for first-line with Imbruvica?
  • How do KOLs view Zydelig compared with Imbruvica in terms of safety and efficacy?
  • In which settings is Zydelig likely to be most effectively used?
  • How will haematologists choose between Zydelig and Imbruvica in the relapsed/refractory setting?
  • Do EU KOLs favour Imbruvica over Zydelig for the treatment of patients with high-risk genetic markers such as the 17p deletion?
  • Will Imbruvica become the standard first-line therapy for patients with high-risk genetic markers in the US?
  • How do KOLs view the potential for combining oral targeted therapies with monoclonal antibodies in the treatment of CLL?

When you purchase the full report, you get access to this Update Bulletin.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.


All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved